


CLAIMS

What is claimed is:

5 1. Use of a compound in the manufacture of a medicament for the treatment of inflammatory bowel disease, said compound comprising



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y

10 is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group; A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be substituted with S or O; or A is  $-(CH_2)_m-Ar-(CH_2)_o-$  wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one  $CH_2$  may be substituted with S or O; and

D is aryl or heteroaryl.

15 2. Use of claim 1 wherein D in said compound is phenyl.


3. Use of claim 2 wherein D in said compound is chlorophenyl.

4. Use of claim 3 wherein D in said compound is 3,5-dichlorophenyl.

5. Use of claim 2 wherein D in said compound is unsubstituted phenyl.

6. Use of claim 1 wherein A in said compound is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ .

20 7. Use of claim 2, said compound comprising




or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

wherein  $R^3$  is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy,  $NH_2$ ,  $OH$ ,  $CN$ ,  $NO_2$ , or  $CF_3$ ; and


25 n is 0, 1, 2, or 3.

8. Use of claim 7, said compound comprising



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;  
wherein a dashed line indicates the presence or absence of a covalent bond.

9. Use of claim 2, said compound comprising




5

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;  
wherein R<sup>3</sup> is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH<sub>2</sub>, OH, CN, NO<sub>2</sub>, or CF<sub>3</sub>;  
R<sup>4</sup> is hydroxyhydrocarbyl having from 1 to 10 carbon atoms; and

10 n is 0, 1, 2, or 3.

10. A compound comprising




or a pharmaceutically acceptable salt or a prodrug thereof.

## AMENDED CLAIMS


Received by the International Bureau on 03 October 2006 (03.10.2006)

What is claimed is:

1. A compound of the formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;


A is  $-(CH_2)_6$ , *cis*  $-CH_2CH=CH-(CH_2)_3$ , or  $-CH_2C\equiv C-(CH_2)_3$ , wherein 1 or 2 carbon atoms may be substituted with S or O; or A is  $-(CH_2)_m-Ar-(CH_2)_o$  wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one  $CH_2$  may be substituted with S or O; and D is aryl or heteroaryl.2. The compound of claim 1 wherein D is phenyl.3. The compound of claim 2 wherein D is chlorophenyl.4. The compound of claim 3 wherein D is 3,5-dichlorophenyl.5. The compound of claim 2 wherein D is unsubstituted phenyl.6. The compound according to any one of claims 1 to 5, wherein A is  $-(CH_2)_6$ , *cis*  $-CH_2CH=CH-(CH_2)_3$ , or  $-CH_2C\equiv C-(CH_2)_3$ .7. The compound of claim 2 having the formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

wherein R^3 is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH\_2, OH, CN, NO\_2, or CF\_3; and


n is 0, 1, 2, or 3.

8. The compound of claim 7 having the formula




or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;  
wherein a dashed line indicates the presence or absence of a covalent bond.

9. The compound of claim 2 having the formula



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;  
wherein R<sup>3</sup> is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH<sub>2</sub>, OH, CN, NO<sub>2</sub>, or CF<sub>3</sub>;  
R<sup>4</sup> is hydroxyhydrocarbyl having from 1 to 10 carbon atoms; and  
n is 0, 1, 2, or 3.

10. The compound of claim 9 having the formula



or a pharmaceutically acceptable salt or a prodrug thereof.

11. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prevention of glaucoma or ocular hypertension.

12. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prevention of for the treatment of inflammatory bowel disease.

13. A liquid comprising a compound according to any one of claims 1 to 10, wherein said liquid is ophthalmically acceptable.